



September 2025

Clinical Trial News

Austin Clinical Research (ACR) is currently enrolling patients diagnosed with the Wet & Dry forms of Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, and Diabetic Macular Edema. There is no cost for participation, black-car transportation can be provided for study appointments, and patients will receive a stipend for each completed visit when enrolled in a clinical trial.

Meet Our Team



Study Spotlight

Alcon Nova-1

A clinical trial for patients with Wet AMD (Age-Related Macular Degeneration). Current treatments for Wet AMD require frequent injections. This study is trialing an injectable eye insert, which slowly releases medication over time, potentially reducing the number of injections you will need.

4DMT 4FRONT-1

A clinical trial for patients with Wet AMD (Age-Related Macular Degeneration). After 3 FDA-approved injections, patients may receive a one-time gene therapy injection, to potentially reduce or eliminate the number of future injections needed for Wet AMD.

[Watch Video](#)



September 2025

Enrolling Trials

(Click on each study name for more info!)

Dry Age-Related Macular Degeneration (AMD)

[Boehringer Ingelheim 1484-0005 JADE](#)

[Genentech GR44251 GAlette](#)

[Roche BP45482](#)

Wet Age-Related Macular Degeneration (AMD)

[Roche BP41670 Burgundy](#)

[4DMT 4D-150-C003 4Front-1](#)

[Alcon RTE888-E001 Nova-1](#)

Diabetic Macular Edema

[Genentech BP44175 Pregonda](#)

[Genentech GR43828 THAMES](#)

[Boehringer-Ingelheim 1485-0018 Thulite](#)

Diabetic Retinopathy

[Boehringer-Ingelheim 1436-0007 Crimson](#)

[Study Spotlight](#)

Genentech GR44251 GAlette

Austin Clinical Research is now participating in the Genentech GR44251

GAlette study for patients with dry AMD with geographic atrophy (GA).

Through a surgical procedure, new, healthy cells are transplanted to the area of the retina that is damaged from dry AMD. This therapy has the potential for vision restoration.